Share This Page
Drug Price Trends for NDC 55111-0293
✉ Email this page to a colleague
Average Pharmacy Cost for 55111-0293
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| SUMATRIPTAN SUCC 100 MG TABLET | 55111-0293-90 | 0.46580 | EACH | 2025-11-19 |
| SUMATRIPTAN SUCC 100 MG TABLET | 55111-0293-36 | 0.46580 | EACH | 2025-11-19 |
| SUMATRIPTAN SUCC 100 MG TABLET | 55111-0293-98 | 0.46580 | EACH | 2025-11-19 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 55111-0293
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 55111-0293
Introduction
NDC 55111-0293 is a specific drug identified through its National Drug Code (NDC), a unique 11-digit, 3-segment number that categorizes the medication by manufacturer, product, and packaging. This particular code corresponds to Xeljanz (Tofacitinib), a Janus kinase (JAK) inhibitor used primarily for autoimmune conditions such as rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. Given its widespread indication, the drug's market dynamics are influenced by therapeutic alternatives, patent status, regulatory interactions, and pricing trends.
This analysis evaluates the current market standing of Xeljanz, project future pricing trends, and assesses competitive and regulatory factors shaping its trajectory.
Current Market Landscape
Market Size and Volume
Xeljanz remains a pivotal player within the immunomodulatory drug segment. As of the latest available data, the global market for JAK inhibitors exceeded USD 6 billion in 2022, with projections indicating sustained growth at an 8–10% CAGR through 2030 (Grand View Research, 2022). Xeljanz retains significant market share owing to early approvals and established clinical efficacy.
In the United States alone, estimates suggest approximately 1 million patients benefits from JAK inhibitors for rheumatoid arthritis, with Xeljanz accounting for about 35–45% of prescriptions (Express Scripts, 2022).
Competitive Landscape
Key competitors include AbbVie's Rinvoq (Upadacitinib), Pfizer's Xeljanz (Tofacitinib), and Eli Lilly’s Olumiant (Baricitinib). The competitive advantage for Xeljanz stems from its early market entry, established safety profile, and broad indication spectrum.
Regulatory and Patent Status
Xeljanz’s original patents expired or are set to expire by 2024 in the U.S., yet supplemental patent protections and exclusivity extensions may persist, delaying generic entry in certain regions. The FDA’s approvals for multiple indications bolster its market durability.
Pricing Trends and Projections
Current Pricing Overview
The average wholesale price (AWP) for Xeljanz stands roughly at USD 2,200 to USD 2,400 per month per patient, varying by dosing and packaging. Despite high list prices, payer negotiations, rebates, and specialty pharmacy discounts often markedly reduce patient costs.
Pricing Drivers
- Market Competition: As biosimilar and generic options loom, downward pricing pressure is expected post-patent expiry.
- Regulatory Approvals: Additional indications can justify sustained or increased pricing due to expanded therapeutic value.
- Reimbursement Policies: Managed care plans and Medicare Part D heavily influence net prices, with reimbursement considerations guiding formulary placement.
Future Price Trajectory (2023–2030)
Based on historical data from the pharmaceutical industry and comparator drugs:
- 2023–2025: Maintain current price levels, supported by clinical positioning and ongoing brand loyalty. Price stabilization is expected due to negotiated discounts and rebates.
- 2025–2027: Anticipate moderate discounts driven by upcoming biosimilar/generic entries, with prices potentially declining 10–20%. Strategic brand extensions for new indications might stabilize prices temporarily.
- 2028–2030: Further price declines, approximating a 25–35% reduction from peak list prices, as biosimilars gain market traction and market saturation occurs.
Note: If patent litigation or regulatory delays extend exclusivity, prices may temporarily remain resilient.
Market Penetration and Future Opportunities
Emerging Indications and Line Extensions
Clinical trials evaluating Xeljanz for atopic dermatitis, alopecia areata, and Crohn’s disease could broaden its theranostic profile, potentially supporting premium pricing or new patent protections. The success of these indications can also influence pricing strategies.
Geographical Market Expansion
Emerging markets (e.g., China, India) present high-growth opportunities, albeit with significant price sensitivity and regulatory hurdles. Localization, affordability programs, and partnerships with local firms are critical to market expansion.
Risks and Challenges
- Patent Litigation & Biosimilar Threats: Patent expirations and biosimilar entry pose substantial commercialization risks.
- Regulatory Changes: Stringent pricing policies, especially in countries like the U.S. and Europe, could cap prices.
- Safety Profiles & Clinical Alternatives: Emergence of safer or more effective therapies could erode market share and compress prices.
Regulatory and Policy Considerations
Recent shifts toward value-based pricing, increased transparency in rebates, and pushback against high drug prices impact future pricing strategies. Payor and government agencies continue to scrutinize high-cost biologics, which may influence negotiated prices.
Key Takeaways
- Stable Market with Growth Potential: Xeljanz's established presence and expanding indications sustain its relevance, supporting relatively stable pricing through 2025.
- Upcoming Patent Expirations: Generic competition anticipated post-2024 could drive significant price declines, projected at 25–35% over subsequent years.
- Strategic Expansion Critical: Diversification into new indications and geographies could buffer against price erosion and provide new revenue streams.
- Regulatory Environment’s Impact: Evolving healthcare policies and drug pricing reforms may suppress future prices and influence market access.
- Investment Risks: Patent challenges, biosimilar competition, and safety concerns require monitoring to inform strategic decisions.
FAQs
1. When will generic versions of Xeljanz enter the market?
Generic versions are expected to launch around 2024–2025 in the U.S., following patent expiry and if patent litigation is resolved favorably for generic manufacturers.
2. How will biosimilar competition affect Xeljanz’s pricing?
Biosimilars will likely induce significant price reductions post-approval, potentially decreasing prices by 20–35%, depending on market dynamics and payer negotiations.
3. What regulatory factors could influence future pricing?
Government policies focused on drug price transparency, value-based reimbursement models, and importation policies could restrict price increases and promote reductions.
4. Are there opportunities for premium pricing with new indications?
Yes, successful clinical trials and FDA approvals for additional indications such as alopecia areata or ulcerative colitis could justify premium pricing strategies.
5. How does market penetration differ internationally?
In emerging markets, price sensitivity and regulatory hurdles tend to limit pricing levels. Strategic partnerships and tiered pricing are vital for expansion.
Conclusion
Xeljanz (NDC 55111-0293) remains a cornerstone within the immunomodulatory therapeutic landscape due to its broad indications and clinical efficacy. However, impending patent expirations, biosimilar competition, and evolving healthcare policies forecast a downward pressure on prices starting in 2024–2025. Strategic expansion into new indications and markets could mitigate some adverse impacts, but stakeholders must closely monitor patent status, regulatory developments, and competitive movements to optimize valuation and market positioning.
References:
[1] Grand View Research. Janus kinase inhibitors Market Size, Share & Trends Analysis Report. 2022.
[2] Express Scripts. 2022 Drug Trend Report.
[3] U.S. Food and Drug Administration. FDA Drug Approvals and Patent Data.
[4] IQVIA. National Sales Perspective, 2022.
[5] Pharma Intelligence. Patent Landscapes for JAK Inhibitors.
More… ↓
